Improving bladder cancer patient care: a pharmacoeconomic perspective
Gore JL, Gilbert SM.Expert Rev Anticancer Ther. 2013 Jun;13(6):661-8. doi: 10.1586/era.13.58.

Source

Department of Urology, University of Washington, Seattle, WA, USA. jlgore@u.washington.edu.

Abstract

Bladder cancer is the most expensive cancer per capita to treat in the US healthcare system. Substantial costs associated with the diagnosis, management and surveillance of bladder cancer account for the bulk of the expense; yet, for that cost, patients may not receive high-quality care. Herein the authors review the sources of expenditure associated with bladder cancer care, review population-level analyses of the quality of bladder cancer care in the USA, and discuss opportunities for quality improvement that may yield greater value for men and women newly diagnosed with bladder cancer.